

# RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

NCT03118986

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	The Hospital for Sick Children
<b>Enrollment</b>	200 participants

## Key Eligibility Criteria

---

### Inclusion (15)

- Planned receipt of HEC or cyclophosphamide e 1 g/m<sup>2</sup>/day (e 33 mg/kg/day) for cancer treatment or autologous or allogeneic HSCT conditioning.<sup>81,82</sup> Examples of HEC are: busulfan IV (myeloablative dosing), carboplatin e175mg/m<sup>2</sup>/dose, cisplatin e12mg/m<sup>2</sup>/dose, cytarabine e3g/m<sup>2</sup>/day, melphalan \>140mg/m<sup>2</sup>, methotrexate e12g/m<sup>2</sup>/dose and thiotepa e300mg/m<sup>2</sup>/dose.
- Plan for inpatient admission from administration of first study drug dose until 24 hours following administration of last study drug dose.
- Body weight of at least 12.5 kg
- to \< 18 years of age. Note that the minimum age requirement corresponds to an approximate body weight of 12.5 kg.
- Samples for all laboratory tests will be obtained within one week prior to administration of the first chemotherapy dose of the study chemotherapy block or the first HSCT conditioning dose:

... and 10 more (see full listing online)

## Locations (10 total)

---

University of California, San Francisco, California, United States  
The Children's Mercy Hospital, Kansas City, Missouri, United States  
Columbia University/Morgan Stanley Children's Hospital, New York, New York, United States  
... and 7 more locations